Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study

To analyze the long-term outcomes of eyes with neovascular age-related macular degeneration (AMD) starting treatment with vascular endothelial growth factor (VEGF) inhibitors at least 5 years earlier. Database observational study. Treatment-naïve eyes with neovascular AMD tracked by the Fight Retina...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Minn.), 2015-09, Vol.122 (9), p.1837-1845
Hauptverfasser:	Gillies, Mark C, Campain, Anna, Barthelmes, Daniel, Simpson, Judy M, Arnold, Jennifer J, Guymer, Robyn H, McAllister, Ian L, Essex, Rohan W, Morlet, Nigel, Hunyor, Alex P
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Databases, Factual Female Follow-Up Studies Humans Intravitreal Injections Male Registries Retreatment Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	1845
container_issue	9
container_start_page	1837
container_title	Ophthalmology (Rochester, Minn.)
container_volume	122
creator	Gillies, Mark C Campain, Anna Barthelmes, Daniel Simpson, Judy M Arnold, Jennifer J Guymer, Robyn H McAllister, Ian L Essex, Rohan W Morlet, Nigel Hunyor, Alex P
description	To analyze the long-term outcomes of eyes with neovascular age-related macular degeneration (AMD) starting treatment with vascular endothelial growth factor (VEGF) inhibitors at least 5 years earlier. Database observational study. Treatment-naïve eyes with neovascular AMD tracked by the Fight Retinal Blindness outcome registry that received at least 1 anti-VEGF injection. Locally weighted scatterplot smoothing curves were used to display visual acuity (VA) results. Change in mean VA and number of injections and visits from baseline up to 7 years after initiating treatment. The mean follow-up time of all 1212 identified eyes was 53.5 months, and 549 (45%) continued attending after 60 months. Mean VA improved from 55.1 to 61.4 letters after 6 months and remained above the mean presenting VA for approximately 6 years. After 7 years, mean VA was 2.6 letters lower than baseline for the 131 eyes still being followed; 40% had VA ≥70 (20/40) letters, and 18% had VA ≤35 letters (20/200). Of those with 20/40 VA before treatment, 40% had lost it after 7 years. Geographic atrophy affecting the fovea was thought to be the cause of a ≥10-letter loss after 6.5 years in 37% of a subset of such eyes that were retrospectively analyzed. A median of 6 injections and 9 visits were recorded over the first 12 months, and then 5 treatments and 7 to 9 visits per annum thereafter through 7 years. Treatment was discontinued for 663 eyes (53%) within the first 5 years. Despite initial gains in vision, the mean VA of these eyes had deteriorated to baseline or worse around the time treatment was discontinued. The rate of serious adverse events was low. Good long-term outcomes of VEGF inhibition for neovascular AMD were found in this study. These results may be better than other reports because more injections were given to our patients, possibly associated with a greater incentive for the physician to treat. Further studies to determine how to maximize the proportion of eyes that retain the initial VA gains of anti-VEGF are warranted.
doi_str_mv	10.1016/j.ophtha.2015.05.010
format	Article
fullrecord	<record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1706578339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1706578339</sourcerecordid><originalsourceid>FETCH-LOGICAL-p281t-846e8544801151a55684df7e7677f287abdf736228d6b8052eb2cbd595098d143</originalsourceid><addsrcrecordid>eNo1kEtPwzAQhC0kREvhHyDkI5cE2_Er3KrylAqVoJwjJ9n0oSRObadS_z2BFmml3dn5NIdB6IaSmBIq77ex7dZhbWJGqIjJMJScoTEVPI24oskIXXq_JYRImfALNGKSpMMlx2g3t-0qWoJr8KIPhW3AY1vhpQMTGmjDr_gAuze-6Gvj8HQF0SfUJkCJ383x9wgraMGZsLHtA340weDK2QabFi9yD27_55gaf4W-PFyh88rUHq5Pe4K-n5-Ws9dovnh5m03nUcc0DZHmErTgXBNKBTVCSM3LSoGSSlVMK5MPKpGM6VLmmggGOSvyUqSCpLqkPJmgu2Nu5-yuBx-yZuMLqGvTgu19RhWRQukkSQf09oT2eQNl1rlNY9wh-68p-QEI7mmK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1706578339</pqid></control><display><type>article</type><title>Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Gillies, Mark C ; Campain, Anna ; Barthelmes, Daniel ; Simpson, Judy M ; Arnold, Jennifer J ; Guymer, Robyn H ; McAllister, Ian L ; Essex, Rohan W ; Morlet, Nigel ; Hunyor, Alex P</creator><creatorcontrib>Gillies, Mark C ; Campain, Anna ; Barthelmes, Daniel ; Simpson, Judy M ; Arnold, Jennifer J ; Guymer, Robyn H ; McAllister, Ian L ; Essex, Rohan W ; Morlet, Nigel ; Hunyor, Alex P ; Fight Retinal Blindness Study Group</creatorcontrib><description>To analyze the long-term outcomes of eyes with neovascular age-related macular degeneration (AMD) starting treatment with vascular endothelial growth factor (VEGF) inhibitors at least 5 years earlier. Database observational study. Treatment-naïve eyes with neovascular AMD tracked by the Fight Retinal Blindness outcome registry that received at least 1 anti-VEGF injection. Locally weighted scatterplot smoothing curves were used to display visual acuity (VA) results. Change in mean VA and number of injections and visits from baseline up to 7 years after initiating treatment. The mean follow-up time of all 1212 identified eyes was 53.5 months, and 549 (45%) continued attending after 60 months. Mean VA improved from 55.1 to 61.4 letters after 6 months and remained above the mean presenting VA for approximately 6 years. After 7 years, mean VA was 2.6 letters lower than baseline for the 131 eyes still being followed; 40% had VA ≥70 (20/40) letters, and 18% had VA ≤35 letters (20/200). Of those with 20/40 VA before treatment, 40% had lost it after 7 years. Geographic atrophy affecting the fovea was thought to be the cause of a ≥10-letter loss after 6.5 years in 37% of a subset of such eyes that were retrospectively analyzed. A median of 6 injections and 9 visits were recorded over the first 12 months, and then 5 treatments and 7 to 9 visits per annum thereafter through 7 years. Treatment was discontinued for 663 eyes (53%) within the first 5 years. Despite initial gains in vision, the mean VA of these eyes had deteriorated to baseline or worse around the time treatment was discontinued. The rate of serious adverse events was low. Good long-term outcomes of VEGF inhibition for neovascular AMD were found in this study. These results may be better than other reports because more injections were given to our patients, possibly associated with a greater incentive for the physician to treat. Further studies to determine how to maximize the proportion of eyes that retain the initial VA gains of anti-VEGF are warranted.</description><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/j.ophtha.2015.05.010</identifier><identifier>PMID: 26096346</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - adverse effects ; Angiogenesis Inhibitors - therapeutic use ; Databases, Factual ; Female ; Follow-Up Studies ; Humans ; Intravitreal Injections ; Male ; Registries ; Retreatment ; Treatment Outcome ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity - physiology ; Wet Macular Degeneration - drug therapy ; Wet Macular Degeneration - physiopathology</subject><ispartof>Ophthalmology (Rochester, Minn.), 2015-09, Vol.122 (9), p.1837-1845</ispartof><rights>Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26096346$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gillies, Mark C</creatorcontrib><creatorcontrib>Campain, Anna</creatorcontrib><creatorcontrib>Barthelmes, Daniel</creatorcontrib><creatorcontrib>Simpson, Judy M</creatorcontrib><creatorcontrib>Arnold, Jennifer J</creatorcontrib><creatorcontrib>Guymer, Robyn H</creatorcontrib><creatorcontrib>McAllister, Ian L</creatorcontrib><creatorcontrib>Essex, Rohan W</creatorcontrib><creatorcontrib>Morlet, Nigel</creatorcontrib><creatorcontrib>Hunyor, Alex P</creatorcontrib><creatorcontrib>Fight Retinal Blindness Study Group</creatorcontrib><title>Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>To analyze the long-term outcomes of eyes with neovascular age-related macular degeneration (AMD) starting treatment with vascular endothelial growth factor (VEGF) inhibitors at least 5 years earlier. Database observational study. Treatment-naïve eyes with neovascular AMD tracked by the Fight Retinal Blindness outcome registry that received at least 1 anti-VEGF injection. Locally weighted scatterplot smoothing curves were used to display visual acuity (VA) results. Change in mean VA and number of injections and visits from baseline up to 7 years after initiating treatment. The mean follow-up time of all 1212 identified eyes was 53.5 months, and 549 (45%) continued attending after 60 months. Mean VA improved from 55.1 to 61.4 letters after 6 months and remained above the mean presenting VA for approximately 6 years. After 7 years, mean VA was 2.6 letters lower than baseline for the 131 eyes still being followed; 40% had VA ≥70 (20/40) letters, and 18% had VA ≤35 letters (20/200). Of those with 20/40 VA before treatment, 40% had lost it after 7 years. Geographic atrophy affecting the fovea was thought to be the cause of a ≥10-letter loss after 6.5 years in 37% of a subset of such eyes that were retrospectively analyzed. A median of 6 injections and 9 visits were recorded over the first 12 months, and then 5 treatments and 7 to 9 visits per annum thereafter through 7 years. Treatment was discontinued for 663 eyes (53%) within the first 5 years. Despite initial gains in vision, the mean VA of these eyes had deteriorated to baseline or worse around the time treatment was discontinued. The rate of serious adverse events was low. Good long-term outcomes of VEGF inhibition for neovascular AMD were found in this study. These results may be better than other reports because more injections were given to our patients, possibly associated with a greater incentive for the physician to treat. Further studies to determine how to maximize the proportion of eyes that retain the initial VA gains of anti-VEGF are warranted.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Databases, Factual</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Male</subject><subject>Registries</subject><subject>Retreatment</subject><subject>Treatment Outcome</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Visual Acuity - physiology</subject><subject>Wet Macular Degeneration - drug therapy</subject><subject>Wet Macular Degeneration - physiopathology</subject><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtPwzAQhC0kREvhHyDkI5cE2_Er3KrylAqVoJwjJ9n0oSRObadS_z2BFmml3dn5NIdB6IaSmBIq77ex7dZhbWJGqIjJMJScoTEVPI24oskIXXq_JYRImfALNGKSpMMlx2g3t-0qWoJr8KIPhW3AY1vhpQMTGmjDr_gAuze-6Gvj8HQF0SfUJkCJ383x9wgraMGZsLHtA340weDK2QabFi9yD27_55gaf4W-PFyh88rUHq5Pe4K-n5-Ws9dovnh5m03nUcc0DZHmErTgXBNKBTVCSM3LSoGSSlVMK5MPKpGM6VLmmggGOSvyUqSCpLqkPJmgu2Nu5-yuBx-yZuMLqGvTgu19RhWRQukkSQf09oT2eQNl1rlNY9wh-68p-QEI7mmK</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Gillies, Mark C</creator><creator>Campain, Anna</creator><creator>Barthelmes, Daniel</creator><creator>Simpson, Judy M</creator><creator>Arnold, Jennifer J</creator><creator>Guymer, Robyn H</creator><creator>McAllister, Ian L</creator><creator>Essex, Rohan W</creator><creator>Morlet, Nigel</creator><creator>Hunyor, Alex P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20150901</creationdate><title>Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study</title><author>Gillies, Mark C ; Campain, Anna ; Barthelmes, Daniel ; Simpson, Judy M ; Arnold, Jennifer J ; Guymer, Robyn H ; McAllister, Ian L ; Essex, Rohan W ; Morlet, Nigel ; Hunyor, Alex P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p281t-846e8544801151a55684df7e7677f287abdf736228d6b8052eb2cbd595098d143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Databases, Factual</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Male</topic><topic>Registries</topic><topic>Retreatment</topic><topic>Treatment Outcome</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Visual Acuity - physiology</topic><topic>Wet Macular Degeneration - drug therapy</topic><topic>Wet Macular Degeneration - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gillies, Mark C</creatorcontrib><creatorcontrib>Campain, Anna</creatorcontrib><creatorcontrib>Barthelmes, Daniel</creatorcontrib><creatorcontrib>Simpson, Judy M</creatorcontrib><creatorcontrib>Arnold, Jennifer J</creatorcontrib><creatorcontrib>Guymer, Robyn H</creatorcontrib><creatorcontrib>McAllister, Ian L</creatorcontrib><creatorcontrib>Essex, Rohan W</creatorcontrib><creatorcontrib>Morlet, Nigel</creatorcontrib><creatorcontrib>Hunyor, Alex P</creatorcontrib><creatorcontrib>Fight Retinal Blindness Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gillies, Mark C</au><au>Campain, Anna</au><au>Barthelmes, Daniel</au><au>Simpson, Judy M</au><au>Arnold, Jennifer J</au><au>Guymer, Robyn H</au><au>McAllister, Ian L</au><au>Essex, Rohan W</au><au>Morlet, Nigel</au><au>Hunyor, Alex P</au><aucorp>Fight Retinal Blindness Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>122</volume><issue>9</issue><spage>1837</spage><epage>1845</epage><pages>1837-1845</pages><eissn>1549-4713</eissn><abstract>To analyze the long-term outcomes of eyes with neovascular age-related macular degeneration (AMD) starting treatment with vascular endothelial growth factor (VEGF) inhibitors at least 5 years earlier. Database observational study. Treatment-naïve eyes with neovascular AMD tracked by the Fight Retinal Blindness outcome registry that received at least 1 anti-VEGF injection. Locally weighted scatterplot smoothing curves were used to display visual acuity (VA) results. Change in mean VA and number of injections and visits from baseline up to 7 years after initiating treatment. The mean follow-up time of all 1212 identified eyes was 53.5 months, and 549 (45%) continued attending after 60 months. Mean VA improved from 55.1 to 61.4 letters after 6 months and remained above the mean presenting VA for approximately 6 years. After 7 years, mean VA was 2.6 letters lower than baseline for the 131 eyes still being followed; 40% had VA ≥70 (20/40) letters, and 18% had VA ≤35 letters (20/200). Of those with 20/40 VA before treatment, 40% had lost it after 7 years. Geographic atrophy affecting the fovea was thought to be the cause of a ≥10-letter loss after 6.5 years in 37% of a subset of such eyes that were retrospectively analyzed. A median of 6 injections and 9 visits were recorded over the first 12 months, and then 5 treatments and 7 to 9 visits per annum thereafter through 7 years. Treatment was discontinued for 663 eyes (53%) within the first 5 years. Despite initial gains in vision, the mean VA of these eyes had deteriorated to baseline or worse around the time treatment was discontinued. The rate of serious adverse events was low. Good long-term outcomes of VEGF inhibition for neovascular AMD were found in this study. These results may be better than other reports because more injections were given to our patients, possibly associated with a greater incentive for the physician to treat. Further studies to determine how to maximize the proportion of eyes that retain the initial VA gains of anti-VEGF are warranted.</abstract><cop>United States</cop><pmid>26096346</pmid><doi>10.1016/j.ophtha.2015.05.010</doi><tpages>9</tpages></addata></record>
fulltext	fulltext
identifier	EISSN: 1549-4713
ispartof	Ophthalmology (Rochester, Minn.), 2015-09, Vol.122 (9), p.1837-1845
issn	1549-4713
language	eng
recordid	cdi_proquest_miscellaneous_1706578339
source	MEDLINE; Elsevier ScienceDirect Journals Complete
subjects	Aged Aged, 80 and over Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Databases, Factual Female Follow-Up Studies Humans Intravitreal Injections Male Registries Retreatment Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology
title	Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T13%3A31%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Outcomes%20of%20Treatment%20of%20Neovascular%20Age-Related%20Macular%20Degeneration:%20Data%20from%20an%20Observational%20Study&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=Gillies,%20Mark%20C&rft.aucorp=Fight%20Retinal%20Blindness%20Study%20Group&rft.date=2015-09-01&rft.volume=122&rft.issue=9&rft.spage=1837&rft.epage=1845&rft.pages=1837-1845&rft.eissn=1549-4713&rft_id=info:doi/10.1016/j.ophtha.2015.05.010&rft_dat=%3Cproquest_pubme%3E1706578339%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1706578339&rft_id=info:pmid/26096346&rfr_iscdi=true